Daniel Seneor

Dr. Daniel Seneor


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 February 2025 in Metabolites
Verified
Journal Article
Open access
PDF file
BBBruno BRUNO de Mattos Lombardi Badia
Bruno BRUNO de Mattos Lombardi Badia
PSPaulo de Lima Serrano
Paulo de Lima Serrano
JBJoão Paulo Barile
João Paulo Barile
DSDaniel Seneor
Daniel Seneor
PMPatrícia Marques Mendes
Patrícia Marques Mendes
Paulo Victor Sgobbi SouzaPaulo Victor Sgobbi Souza
Paulo Victor Sgobbi Souza
Background: Acute hepatic porphyrias (AHPs) represent inherited metabolic disorders of the heme biosynthesis pathway, leading to neurological and systemic impairment. Despite the presence of well-recognized chronic symptoms and signs, acute neurological, both neuromuscular and central neurological complications pose a significant challenge in clinical practice, with a potential risk of greater severity and mortality during acute decompensation episodes of AHPs. Care related to the prescription of medications, considering the risk of porphyrinogenicity, is a major and recurring concern in the acute and chronic management of AHP patients. Infectious clinical complications are significant issues in both outpatient and hospital settings for patients with AHPs. It is crucial to identify therapeutic regimens with the best safety and efficacy profiles for treating such infectious complications in AHP patients. The scarcity of structured knowledge available in guidelines and recommendations often leads to the use of therapeutic options with higher potential risks in treating patients with AHPs. Objectives: This review article aims to provide practical recommendations for managing the most significant infectious complications in clinical practice, with a focus on their impact on the clinical care of patients with AHPs.

6 February 2025 in Medical Sciences
Verified
Journal Article
Open access
PDF file
PSPaulo de Lima Serrano
Paulo de Lima Serrano
BBBruno BRUNO de Mattos Lombardi Badia
Bruno BRUNO de Mattos Lombardi Badia
JBJoão Paulo Barile
João Paulo Barile
PMPatrícia Marques Mendes
Patrícia Marques Mendes
RCRenan Brandão Rambaldi Cavalheiro
Renan Brandão Rambaldi Cavalheiro
Paulo Victor Sgobbi SouzaPaulo Victor Sgobbi Souza
Paulo Victor Sgobbi Souza
Secondary hypertension and resistant hypertension may result from potentially treatable acquired or hereditary diseases. Inherited Metabolic Disorders are not routinely included in the differential diagnosis of these contexts associated with hypertension, despite the key importance of diagnosis for several of them which enable the early treatment of them. We aim to discuss the current evidence that indicates that a significant portion of cases of unknown resistant hypertension or suspected secondary hypertension may result from unrecognized Acute Hepatic Porphyria (AHP). Diagnostic work-up for AHP is not routinely performed during the evaluation of patients with resistant or refractory hypertension nor in the investigation of secondary hypertension. AHP may present both with neurological and systemic involvement, and hypertension may be observed as part of acute dysautonomia during acute neurovisceral attacks and as a chronic complication during disease course. As AHP represent a potentially treatable group of metabolic disorders, clinicians should consider the inclusion of this group in the diagnostic evaluation of patients with secondary or resistant hypertension.

9 June 2026 in Genes
Verified
Journal Article
Open access
PDF file
DSDaniel Seneor
Daniel Seneor
JBJoão Paulo Barile
João Paulo Barile
PMPatricia Marques Mendes
Patricia Marques Mendes
MOMarco Orsini
Marco Orsini
ESEduardo Mendonça Werneck da Silva
Eduardo Mendonça Werneck da Silva
Paulo Victor Sgobbi SouzaPaulo Victor Sgobbi Souza
Paulo Victor Sgobbi Souza
Arthrogryposis multiplex congenita (AMC) is a diverse group of conditions characterized by multiple joint contractures. Although individually rare, these disorders are estimated to affect 1 in 3000–5000 live births. Their common pathophysiological mechanism is fetal akinesia, a sustained reduction of fetal movement that may arise from intrinsic disturbances—such as central nervous system malformations, motor neuronopathies, neuropathies, neuromuscular junction defects, congenital myopathies, muscular dystrophies, or metabolic diseases—or from extrinsic factors including uterine constraint, maternal illness, infections, or toxic exposures. Reduced fetal motion leads to relatively uniform clinical manifestations, known as the fetal akinesia deformation sequence (FADS), which is characterized by craniofacial anomalies, pulmonary hypoplasia, growth restriction, and contractures. Currently, AMC is classified by clinical features, such as distal arthrogryposis or lethal congenital contracture syndromes. However, advances in molecular genetics have shown wide variability among conditions classified into the same category. Prognosis is widely variable, ranging from lethal perinatal forms to non-progressive mild conditions. This review discusses AMC etiologies from a topographic standpoint, considering the different levels of the motor system involved, by combining current clinical, genetic, and pathophysiological information.